Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer
Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights the performance and clinical impact of Valar Labs’ Vesta platform in prognosticating outcomes for patients with high grade Ta non muscle invasive bladder cancer, a population frequently on the borderline of guideline-based risk stratification who may receive different treatment depending on which guideline their provider uses.
Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers
Valar Labs, the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing. The funding follows Valar Labs’ completion of a recent international, multi-institution validation study and subsequent launch of Vesta, the first AI-based diagnostic test to predict response to first line treatment in bladder cancer. The Series A financing round was led by leading venture capital firms DCVC and Andreessen Horowitz (a16z) Bio + Health with participation from Pear VC. Vineeta Agarwala, MD, PhD, General Partner at a16z Bio + Health, and James Hardiman, General Partner at DCVC, will be joining the Board of Directors.
Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer
Valar Labs, the developer of computational histology AI tests for predicting response to cancer therapies, announced new data today which is being presented on Saturday, May 4, 2024 at the 2024 Annual Meeting of the American Urological Association (AUA) as a podium presentation (PD30-03). The study demonstrated that the first-ever computational histology AI (CHAI) assay with biomarkers for response prediction in bladder cancer can help urologists make more informed treatment decisions for their patients. The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
